151 related articles for article (PubMed ID: 15862506)
1. Risk counseling and management in patients with lobular carcinoma in situ.
Garreau JR; Nelson J; Look R; Walts D; Mahin D; Homer L; Johnson N
Am J Surg; 2005 May; 189(5):610-4; discussion 614-5. PubMed ID: 15862506
[TBL] [Abstract][Full Text] [Related]
2. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
3. Lobular carcinoma in situ.
Afonso N; Bouwman D
Eur J Cancer Prev; 2008 Aug; 17(4):312-6. PubMed ID: 18562954
[TBL] [Abstract][Full Text] [Related]
4. The impact of lobular carcinoma in situ in association with invasive breast cancer on the rate of local recurrence in patients with early-stage breast cancer treated with breast-conserving therapy.
Jolly S; Kestin LL; Goldstein NS; Vicini FA
Int J Radiat Oncol Biol Phys; 2006 Oct; 66(2):365-71. PubMed ID: 16965988
[TBL] [Abstract][Full Text] [Related]
5. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carcinoma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy.
Adepoju LJ; Symmans WF; Babiera GV; Singletary SE; Arun B; Sneige N; Pusztai L; Buchholz TA; Sahin A; Hunt KK; Meric-Bernstam F; Ross MI; Ames FC; Kuerer HM
Cancer; 2006 Jan; 106(1):42-50. PubMed ID: 16333852
[TBL] [Abstract][Full Text] [Related]
6. [Lobular carcinoma in situ (LCIS): risk factor and precursor of invasive lobular breast cancer].
Aulmann S; Penzel R; Schirmacher P; Sinn HP
Verh Dtsch Ges Pathol; 2007; 91():208-13. PubMed ID: 18314616
[TBL] [Abstract][Full Text] [Related]
7. Lobular carcinoma in situ (LCIS): pathology and treatment.
Gump FE
J Cell Biochem Suppl; 1993; 17G():53-8. PubMed ID: 8007710
[TBL] [Abstract][Full Text] [Related]
8. Bilateral risk for subsequent breast cancer after lobular carcinoma-in-situ: analysis of surveillance, epidemiology, and end results data.
Chuba PJ; Hamre MR; Yap J; Severson RK; Lucas D; Shamsa F; Aref A
J Clin Oncol; 2005 Aug; 23(24):5534-41. PubMed ID: 16110014
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic implications of E-cadherin reactivity in patients with lobular carcinoma in situ of the breast.
Goldstein NS; Kestin LL; Vicini FA
Cancer; 2001 Aug; 92(4):738-47. PubMed ID: 11550142
[TBL] [Abstract][Full Text] [Related]
10. Current management of lobular carcinoma in situ of the breast.
Osborne MP; Hoda SA
Oncology (Williston Park); 1994 Feb; 8(2):45-9; discussion 49, 53-4. PubMed ID: 8167087
[TBL] [Abstract][Full Text] [Related]
11. [In situ carcinomas of the breast: clinical features and therapeutic strategies].
Attene F; Scognamillo F; Trignano E; Meloni GB; Rubino C; Trignano M
Ann Ital Chir; 2006; 77(1):3-10; discussion 10-2. PubMed ID: 16910353
[TBL] [Abstract][Full Text] [Related]
12. Clonality of lobular carcinoma in situ (LCIS) and metachronous invasive breast cancer.
Aulmann S; Penzel R; Longerich T; Funke B; Schirmacher P; Sinn HP
Breast Cancer Res Treat; 2008 Feb; 107(3):331-5. PubMed ID: 17380381
[TBL] [Abstract][Full Text] [Related]
13. 8. The dilemma of in situ carcinoma of the breast.
Fentiman IS
Int J Clin Pract; 2001 Dec; 55(10):680-3. PubMed ID: 11777293
[TBL] [Abstract][Full Text] [Related]
14. Recommendations for women with lobular carcinoma in situ (LCIS).
Oppong BA; King TA
Oncology (Williston Park); 2011 Oct; 25(11):1051-6, 1058. PubMed ID: 22106556
[TBL] [Abstract][Full Text] [Related]
15. Results of MRI screening for breast cancer in high-risk patients with LCIS and atypical hyperplasia.
Port ER; Park A; Borgen PI; Morris E; Montgomery LL
Ann Surg Oncol; 2007 Mar; 14(3):1051-7. PubMed ID: 17206485
[TBL] [Abstract][Full Text] [Related]
16. Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project: twelve-year observations concerning lobular carcinoma in situ.
Fisher ER; Land SR; Fisher B; Mamounas E; Gilarski L; Wolmark N
Cancer; 2004 Jan; 100(2):238-44. PubMed ID: 14716756
[TBL] [Abstract][Full Text] [Related]
17. High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients.
Vincent-Salomon A; Hajage D; Rouquette A; Cédenot A; Gruel N; Alran S; Sastre-Garau X; Sigal-Zafrani B; Fourquet A; Kirova Y
Breast; 2012 Jun; 21(3):380-3. PubMed ID: 22531230
[TBL] [Abstract][Full Text] [Related]
18. [A follow-up study about 52 cases of atypical lobular hyperplasia and lobular carcinoma in situ of the breast].
Li HY; Ren GS; Arnould N; Brettes JP
Zhonghua Wai Ke Za Zhi; 2007 Jul; 45(13):874-6. PubMed ID: 17953828
[TBL] [Abstract][Full Text] [Related]
19. Expression of ERalpha and ERbeta in lobular carcinoma in situ.
Middleton LP; Perkins GH; Tucker SL; Sahin AA; Singletary SE
Histopathology; 2007 Jun; 50(7):875-80. PubMed ID: 17543077
[TBL] [Abstract][Full Text] [Related]
20. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk.
King TA; Pilewskie M; Muhsen S; Patil S; Mautner SK; Park A; Oskar S; Guerini-Rocco E; Boafo C; Gooch JC; De Brot M; Reis-Filho JS; Morrogh M; Andrade VP; Sakr RA; Morrow M
J Clin Oncol; 2015 Nov; 33(33):3945-52. PubMed ID: 26371145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
